Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Achillion Pharmaceuticals Inc (ACHN), Tenax Therapeutics Inc (TENX): Peter Kolchinsky’s Latest Equity Moves

RA Capital Management has continued the sale of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares. In a recent wave of reductions, the fund has dumped approximately 2.37 million shares in 10 transactions at prices varying between $10.95 and $11.29 apiece, according to a recent Form 4 filing. As a result, RA Capital Management is left holding 8.03 million shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In another move, the fund’s manager, Peter Kolchinsky, has initiated a position in Tenax Therapeutics Inc (NASDAQ:TENX). According to a recent filing with the Securities and Exchange Commission, RA Capital has acquired 2.26 million shares, which give it control over 8.1% of the company’s common stock.

Peter Kolchinsky

While Kolchinsky has been dumping Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares, Stephen Dubois has been building a new position for his fund during the second quarter of 2014. In its latest 13F filing, Camber Capital Management has disclosed ownership of 5.8 million shares worth $43.9 million. Bain Capital, the manager of Brookside Capital, has also initiated a position during the same period of time and has amassed 2.24 million shares valued at more than $17 million. Daniel Gold, on the other hand, has chosen to reduce his exposure to Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and has slashed his stake by almost a third. His fund, QVT Financial, was left with 7.39 million shares worth in excess of $55.9 million.

No other fund that we track has invested in Tenax Therapeutics Inc (NASDAQ:TENX). The company has a market cap of $104 million and does not pay a dividend. No revenues were registered during the three months ending July 31, 2014 and Tenax Therapeutics Inc (NASDAQ:TENX) has posted a loss of $0.08 per share. The loss is expected to widen to $0.12 per share during the current quarter and no revenues is expected to be announced. On September 22, the company announced the start of Phase 3 testing of levosimendan, which is expected to reduce morbidity and mortality in cardiac surgery patients who risk developing low cardiac output syndrome.

Disclosure: none.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.